Tred Avon Family Wealth LLC Takes Position in Labcorp Holdings Inc. $LH

Tred Avon Family Wealth LLC bought a new position in Labcorp Holdings Inc. (NYSE:LH) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,954 shares of the medical research company’s stock, valued at approximately $521,000.

A number of other large investors have also recently made changes to their positions in LH. REAP Financial Group LLC raised its position in Labcorp by 20.4% in the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after purchasing an additional 37 shares during the period. Hilltop Holdings Inc. boosted its position in shares of Labcorp by 2.6% during the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock valued at $409,000 after buying an additional 41 shares during the period. Pinnacle Associates Ltd. boosted its position in shares of Labcorp by 3.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock valued at $282,000 after buying an additional 42 shares during the period. Larson Financial Group LLC grew its stake in shares of Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock valued at $44,000 after buying an additional 42 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of Labcorp by 7.6% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 668 shares of the medical research company’s stock valued at $168,000 after buying an additional 47 shares during the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Price Performance

Labcorp stock opened at $279.60 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The stock has a market cap of $22.93 billion, a price-to-earnings ratio of 24.77, a price-to-earnings-growth ratio of 1.90 and a beta of 0.90. The firm has a 50-day moving average of $261.22 and a two-hundred day moving average of $265.68. Labcorp Holdings Inc. has a 1 year low of $241.81 and a 1 year high of $293.72.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period last year, the company posted $3.84 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date was Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Insider Buying and Selling at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. The trade was a 5.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the sale, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on LH shares. Robert W. Baird set a $334.00 price target on Labcorp in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.